Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab
| Autor: | Landmesser, U., McGinniss, J., Steg, P.G., Bhatt, D.L., Bittner, V.A., Diaz, R., Dilic, M., Goodman, S.G., Jukema, J.W., Loy, M., Pecin, I., Pordy, R., Poulsen, S.H., Szarek, M., White, H.D., Schwartz, G.G., ODYSSEY OUTCOMES Investigators |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Epidemiology
EZETIMIBE Cholesterol LDL Guidelines Ezetimibe THERAPY Treatment Outcome Double-Blind Method DENSITY-LIPOPROTEIN CHOLESTEROL LDL cholesterol Humans lipids (amino acids peptides and proteins) Acute coronary syndrome Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine Goals Alirocumab |
| Zdroj: | ODYSSEY OUTCOMES Investigators 2022, ' Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab ', European Journal of Preventive Cardiology, vol. 29, no. 14 . https://doi.org/10.1093/eurjpc/zwac107 European Journal of Preventive Cardiology, 29(14), 1842-1851. OXFORD UNIV PRESS |
| ISSN: | 0166-3402 |
| Popis: | Aims European guidelines set low-density lipoprotein cholesterol (LDL-C) treatment goals Methods and results The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18 924 patients with recent ACS and hyperlipidaemia despite high-intensity or maximum-tolerated statin therapy. This subanalysis comprised 17 589 patients with LDL-C ≥1.4 mmol/L at baseline who did not receive ezetimibe treatment. High-intensity statin treatment was used in 88.8%. Median (interquartile range) baseline LDL-C was 2.3 (1.9−2.7) mmol/L. With alirocumab, 94.6% of patients achieved LDL-C Conclusion Among patients with recent ACS and LDL-C ≥1.4 mmol/L despite optimized statin therapy, the addition of alirocumab allowed 94.6% to achieve the 2019 European guideline LDL-C goal |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|